X-Linked Recessive Adrenomyeloneuropathy (AMN)

X-linked recessive adrenomyeloneuropathy (AMN) is a lifelong, inherited nerve and adrenal gland disorder that mostly affects people who have one X chromosome (typically males). It is caused by harmful changes (pathogenic variants) in the ABCD1 gene. This gene helps move very-long-chain fatty acids (VLCFAs) into tiny recycling centers in our cells called peroxisomes. When the transporter does not work, VLCFAs build up in the spinal cord, brain white matter, adrenal glands, and testicular Leydig cells. Over time, this damages the long nerve fibers that control walking (myelopathy) and the peripheral nerves (neuropathy), and it can damage the adrenal glands, causing adrenal insufficiency. Symptoms usually begin in early to mid-adulthood with stiff, spastic legs, trouble walking, numbness or burning in the feet, bladder or sexual problems, and fatigue. Some people also develop inflammatory brain disease (cerebral involvement) that can cause vision, thinking, or behavior changes. The disorder progresses slowly for many years. Early recognition allows monitoring and treatment of adrenal failure and timely evaluation for brain disease.

X-linked recessive adrenomyeloneuropathy (AMN) is a genetic disorder that mostly affects males. It is caused by changes (mutations) in the ABCD1 gene. This gene makes a protein that sits on the wall of tiny cell parts called peroxisomes. When the gene does not work, the body cannot break down very-long-chain fatty acids (VLCFAs). These fatty acids build up in the body, especially in the spinal cord, nerves, and adrenal glands. Over time, this can cause stiffness and weakness of the legs, balance problems, pain or numbness, bladder and bowel problems, and sexual problems. Many patients also develop adrenal gland failure (Addison’s disease), which can cause fatigue, low blood pressure, and darkening of the skin. Some people also get brain inflammation (cerebral ALD), but AMN itself mainly affects the spinal cord and long nerves. Diagnosis uses blood tests for VLCFAs, genetic testing of ABCD1, and MRI/nerve studies. Treatment focuses on adrenal hormone replacement and supportive care; a gene therapy and bone-marrow transplant help the cerebral form, not AMN. NCBIPMCScienceDirectAmerican Academy of Neurology

---

Another names

AMN is also called adrenomyeloneuropathy, X-linked adrenoleukodystrophy—spinal/adult form, ABCD1-related myeloneuropathy, spinal form of X-ALD, or adult ALD. In older writings it may appear under Lorenzo’s oil disease (a broad lay term for X-ALD conditions). When brain inflammation is present, clinicians may say cerebral AMN. When only the adrenal glands are affected at first, it may be called Addison-only ALD. All of these labels refer to conditions on the ABCD1 spectrum; AMN specifically highlights the predominant spinal cord and peripheral nerve involvement with or without adrenal failure.

---

Types

1. Pure (spinal) AMN:
   The most common adult presentation. Slowly progressive stiffness, spasticity, and weakness in both legs, gait imbalance, vibration loss in the feet, bladder urgency, erectile dysfunction, and fatigue. Adrenal insufficiency may or may not be present.

2. AMN with adrenal insufficiency:
   Same spinal symptoms plus low cortisol from adrenal damage. People can have salt craving, weight loss, darkening of skin, low blood pressure, and risk of adrenal crisis during illness.

3. Cerebral AMN (inflammatory brain involvement on top of AMN):
   In some adults, inflammatory demyelination develops in the brain white matter. Vision, hearing, memory, attention, mood, and behavior can change more quickly than the spinal symptoms.

4. Addison-only (early endocrine) phenotype within ABCD1 spectrum:
   Some individuals first present only with adrenal failure (often in childhood or adolescence) and later develop AMN features in adulthood.

5. Symptomatic female carriers (X-linked heterozygotes):
   Many adult females with one mutated ABCD1 copy develop a milder, later-onset myeloneuropathy (stiff gait, sensory loss, bladder symptoms). Adrenal failure and cerebral disease are less common but can occur.

---

Causes

Note: The root cause of AMN is a pathogenic variant in ABCD1. The items below explain that cause and the many biological steps and modifiers that help produce symptoms. They are not separate, unrelated causes.

1. Pathogenic variants in ABCD1: The primary cause. Faulty peroxisomal membrane transporter (ALDP) cannot import VLCFA-CoA into peroxisomes.

2. VLCFA accumulation: C26:0 and related fatty acids build up in plasma, myelin, adrenal cortex, and Leydig cells, stressing cell membranes.

3. Peroxisomal β-oxidation failure: The broken transport step blocks normal breakdown of VLCFAs.

4. Axonopathy of long tracts: Long spinal cord pathways (corticospinal tracts) degenerate, causing spastic paraparesis.

5. Myelin instability: VLCFAs disrupt myelin lipids, making white matter vulnerable.

6. Oxidative stress: Excess VLCFAs drive reactive oxygen species, damaging proteins, lipids, and DNA.

7. Mitochondrial dysfunction (secondary): Energy failure in neurons and glia worsens weakness and fatigue.

8. Neuroinflammation: Microglia and immune cells become activated, especially in cerebral forms.

9. Adrenal cortical cell toxicity: VLCFAs injure zona fasciculata/reticularis cells, lowering cortisol production.

10. Impaired steroidogenesis: Enzyme pathways in steroid production are functionally hampered by toxic lipid buildup.

11. Endothelial and blood–brain barrier stress: White-matter inflammation can accelerate when the barrier is leaky.

12. Hormonal stressors (e.g., illness, surgery): Can unmask or worsen adrenal insufficiency.

13. Fever or severe systemic infection: Raises metabolic demand and can trigger adrenal crisis.

14. Head trauma or severe stress: May precipitate or reveal neurologic deficits by increasing CNS demand.

15. Nutritional imbalance (very high saturated fat intake): Does not cause AMN, but may worsen VLCFA load.

16. Aging: Natural myelin and axon vulnerability increase with age, amplifying AMN effects.

17. Genetic modifiers (outside ABCD1): Other genes may modify inflammation or lipid handling, changing severity.

18. Environmental toxins (solvents/heavy metals): Can add oxidative stress to already vulnerable neurons.

19. Sedentary lifestyle/deconditioning: Not a cause of AMN, but worsens spasticity, balance, and fatigue.

20. Delayed diagnosis/untreated adrenal failure: Prolonged cortisol deficiency leads to worse weakness, fatigue, and crises.

---

Symptoms

1. Stiff, spastic legs: Tight muscles and increased tone make walking effortful.

2. Gait imbalance and frequent tripping: Damage to long tracts and sensory fibers affects coordination.

3. Leg weakness (more than arm): Especially hip flexors and ankle dorsiflexors; slow progression.

4. Numbness, tingling, or burning in feet: Length-dependent peripheral neuropathy.

5. Loss of vibration and position sense in toes/ankles: Posterior column involvement.

6. Leg cramps and painful spasms: Hyper-excitability of motor pathways.

7. Urinary urgency or incontinence: Spinal pathways that control bladder are impaired.

8. Constipation or bowel dysfunction: Autonomic and pelvic floor involvement.

9. Erectile dysfunction and reduced fertility: Autonomic dysfunction and Leydig cell injury.

10. Fatigue and exercise intolerance: Combination of adrenal insufficiency, deconditioning, and neural energy failure.

11. Skin darkening and salt craving (with adrenal failure): Signs of low cortisol with high ACTH.

12. Low blood pressure or dizziness on standing: Adrenal insufficiency and autonomic involvement.

13. Foot deformities (less common): Longstanding neuropathy may change foot posture.

14. Cognitive or behavior change (in cerebral AMN): Problems with attention, processing speed, or mood.

15. Vision or hearing changes (in cerebral AMN): Inflammatory demyelination can affect visual/auditory pathways.

---

Diagnostic tests

A) Physical examination (bedside, observed by the clinician)

1. General observation and vitals (including standing blood pressure):
   The clinician looks for skin darkening, thin body habitus, fatigue, and measures blood pressure lying and standing. A drop on standing suggests adrenal insufficiency or autonomic dysfunction.

2. Gait analysis:
   Walking pattern often shows a stiff, scissoring gait with reduced foot clearance. Timed walking can monitor progression over months to years.

3. Muscle tone and spasticity assessment:
   Increased resistance to passive movement (spasticity) in hip adductors, hamstrings, and calf muscles is typical. This explains leg stiffness and cramps.

4. Muscle strength testing (manual muscle testing):
   The examiner grades strength in key muscle groups. Hip flexion and ankle dorsiflexion weakness are common. Serial exams track change.

5. Deep tendon reflexes and pathologic reflexes:
   Knee and ankle reflexes are brisk; ankle clonus and positive Babinski signs show damage to corticospinal tracts.

6. Sensory exam (light touch, pin, vibration, proprioception):
   Loss of vibration at toes/ankles and reduced position sense reflect dorsal column and peripheral nerve involvement.

7. Coordination and balance (finger-to-nose, heel-to-shin, Romberg):
   Wobbling with eyes closed (positive Romberg) indicates sensory ataxia. Heel-to-shin may be slow or inaccurate.

B) Manual/functional bedside tests and scales

8. Timed Up-and-Go (TUG):
   Measures how long it takes to stand up, walk 3 meters, turn, return, and sit. Longer times reflect functional walking difficulty.

9. 10-Meter Walk Test (comfortable and fast pace):
   Simple speed tests capture gait impairment and respond to rehab.

10. Modified Ashworth Scale for spasticity:
    A standardized rating of resistance to passive stretch. Helpful for tracking spasticity and guiding therapy (e.g., baclofen, botulinum toxin).

11. 128-Hz tuning fork vibration test:
    A practical way to quantify vibration loss at the great toe and ankle. Decline suggests progression of large-fiber neuropathy or dorsal column involvement.

12. Orthostatic vital sign maneuver:
    Blood pressure and heart rate are measured supine and after standing. Significant drops plus symptoms support adrenal insufficiency or autonomic failure.

C) Laboratory and pathological tests

13. Plasma very-long-chain fatty acids (VLCFAs):
    Elevated C26:0 and high C24:0/C22:0 and C26:0/C22:0 ratios are classic biochemical markers of ABCD1 disorders, including AMN.

14. ACTH and morning cortisol:
    High ACTH with low cortisol indicates primary adrenal insufficiency. This test is critical because untreated adrenal failure is dangerous.

15. Standard 250-µg ACTH stimulation (cosyntropin) test:
    Measures cortisol response to synthetic ACTH. A poor rise confirms adrenal failure even if baseline cortisol is borderline.

16. Plasma renin and aldosterone (± electrolytes):
    Helps evaluate mineralocorticoid function. Hyponatremia, hyperkalemia, and high renin with low aldosterone suggest adrenal involvement.

17. ABCD1 gene testing (sequencing ± deletion/duplication analysis):
    Confirms the diagnosis and allows family counseling and carrier testing. Many different variants can cause the disease.

18. Newborn screening metabolite (C26:0-lysophosphatidylcholine) where available:
    Identifies affected infants early, allowing life-long monitoring. Adults may be diagnosed later due to symptoms.

19. Fibroblast peroxisomal studies (specialized):
    Skin fibroblasts can show defective VLCFA metabolism and help in tricky cases or research settings.

20. Rule-out tests for look-alikes (B12, copper, HTLV-1, autoimmune adrenal antibodies):
    These do not diagnose AMN but exclude other causes of myeloneuropathy or adrenal failure that can mimic parts of the picture.

D) Electrodiagnostic tests

21. Nerve conduction studies (NCS):
    Often show a length-dependent axonal sensory>motor neuropathy in the legs. This explains numbness and sensory loss.

22. Electromyography (EMG):
    Looks for chronic denervation in distal leg muscles. Helps separate spasticity-driven weakness from peripheral nerve damage.

23. Somatosensory evoked potentials (SSEPs):
    Slowed conduction from the ankle/knee to the cortex suggests dorsal column pathway dysfunction.

24. Visual evoked potentials (VEPs):
    Useful if vision is changing or brain MRI shows occipital white-matter lesions. Delays suggest demyelination of visual pathways.

25. Autonomic function testing (tilt-table, heart-rate variability, QSART):
    Evaluates orthostatic intolerance, sweat function, and cardio-vagal control—systems often affected in AMN.

E) Imaging tests

26. Brain MRI with and without contrast:
    Looks for symmetrical T2/FLAIR hyperintensities in parieto-occipital (or frontal) white matter. Contrast enhancement at lesion edges suggests active inflammation (cerebral AMN).

27. Spinal cord MRI:
    May show thinning (atrophy) of the thoracic cord without a focal compressive lesion. This supports a degenerative myelopathy rather than a surgical problem.

28. Adrenal imaging (CT or MRI) when indicated:
    Usually normal size or small; imaging helps rule out other adrenal diseases if lab results are unclear.

29. Diffusion tensor imaging (DTI) or MR spectroscopy (specialized):
    Research-level tools that can quantify white-matter integrity and metabolic changes (e.g., reduced N-acetylaspartate).

30. Testicular ultrasound (selected cases):
    Considered if infertility or endocrine issues require evaluation; Leydig cell dysfunction is part of the ABCD1 spectrum.

Non-pharmacological treatments

1) Task-oriented gait training (physiotherapy).
Description (≈150 words): Regular, repeated practice of real-life walking tasks—start/stop, turning, uneven surfaces, slopes, stairs—guided by a physiotherapist. Use of metronome or stepping targets improves rhythm. Short, frequent sessions (for example, 20–30 minutes, 4–5 days/week) help the brain and spinal cord use remaining pathways better. Safety devices (harness, rails) reduce fall fear so patients can train more confidently.
Purpose: Improve safe walking and decrease falls.
Mechanism: Motor learning and neuroplasticity through high-repetition, task-specific practice; improved strength and coordination; reduced co-contraction.
Benefits: Faster, safer gait; better confidence; fewer falls; easier community mobility. PMC

2) Spasticity stretching program (physiotherapy).
Description: Daily slow stretches for calves, hamstrings, hip flexors, and adductors; each stretch held 30–60 seconds and repeated. Use night splints or adjustable ankle-foot orthoses if contractures threaten.
Purpose: Reduce stiffness and prevent fixed contractures.
Mechanism: Lengthens muscle-tendon units; lowers stretch reflex sensitivity; maintains joint range.
Benefits: Smoother steps, less pain, easier hygiene and dressing.

3) Progressive resistance training (physiotherapy).
Description: Supervised strengthening 2–3 times/week for hip extensors, abductors, knee flexors/extensors, dorsiflexors, trunk stabilizers; start low resistance and progress.
Purpose: Restore anti-gravity power and endurance.
Mechanism: Muscle hypertrophy and motor unit recruitment.
Benefits: Better transfers, stair climbing, walking distance.

4) Balance training with perturbations (physiotherapy).
Description: Static and dynamic balance drills on firm/foam surfaces with controlled nudge-like disturbances; add head turns and dual tasks.
Purpose: Prevent falls and improve reactive balance.
Mechanism: Trains vestibular, visual, proprioceptive integration.
Benefits: Fewer falls; safer outdoor and night walking.

5) Ankle-foot orthosis (AFO) or functional electrical stimulation for foot-drop (physiotherapy/assistive).
Description: Lightweight AFO to hold the ankle neutral or peroneal-nerve FES to lift the foot during swing.
Purpose: Reduce tripping and toe drag.
Mechanism: External support or timed stimulation to replace weak dorsiflexion.
Benefits: Safer, faster gait; less energy cost.

6) Core stability and posture training (physiotherapy).
Description: Focused exercises for deep trunk muscles, pelvis control, and thoracic extension; include breathing work.
Purpose: Reduce sway and back pain; support gait.
Mechanism: Improves proximal control; optimizes force transfer.
Benefits: Better endurance, less fatigue and pain.

7) Aerobic conditioning (physiotherapy).
Description: Low-impact cycling, treadmill, or arm-ergometer 20–30 minutes, 3–5 days/week at moderate intensity.
Purpose: Improve endurance and reduce fatigue.
Mechanism: Cardiovascular and mitochondrial adaptations.
Benefits: Longer walking distance; better mood and sleep.

8) Spasticity self-management (physiotherapy education).
Description: Teach triggers (full bladder, infections, tight clothes, sudden moves) and daily tone-relaxing positions.
Purpose: Cut down on spasms at home.
Mechanism: Avoids reflex triggers; uses prolonged muscle lengthening.
Benefits: Fewer painful spasms; better function.

9) Falls-prevention program (physiotherapy/OT).
Description: Home safety review, lighting, footwear, grab bars, shower chair; practice safe transfers.
Purpose: Prevent injuries.
Mechanism: Environmental and behavioral risk reduction.
Benefits: Fewer ER visits; independence.

10) Bladder and bowel retraining (rehab/OT).
Description: Timed voiding, pelvic-floor exercises, adequate fluids/fiber, constipation plan.
Purpose: Reduce urgency/leakage and constipation.
Mechanism: Conditioning pelvic reflexes; stool softening.
Benefits: Better continence; fewer UTIs.

11) Pain management with physical modalities.
Description: Heat/cold packs, TENS, gentle massage, desensitization for neuropathic pain.
Purpose: Reduce pain without drugs.
Mechanism: Gate control; improved circulation; reduced muscle guarding.
Benefits: Better sleep and mobility.

12) Energy conservation & pacing (OT).
Description: Break tasks, sit when possible, plan rests, rearrange home for minimal effort.
Purpose: Beat fatigue.
Mechanism: Matches energy supply with demand.
Benefits: More meaningful activity with less exhaustion.

13) Vocational and driving rehab (OT).
Description: Workplace adaptations; hand controls for cars; evaluation and training.
Purpose: Keep employment and driving independence.
Mechanism: Ergonomics and adaptive equipment.
Benefits: Quality of life and income stability.

14) Bone health plan (physio/endocrine/OT).
Description: Weight-bearing as able, vitamin D/calcium intake, safe sunlight, fall-proofing.
Purpose: Protect bones in low mobility or steroid use.
Mechanism: Mechanical loading and nutrient support.
Benefits: Fewer fractures.

15) Home exercise + tele-rehab follow-up (physiotherapy).
Description: Simple daily plan with video check-ins to progress safely.
Purpose: Maintain gains between visits.
Mechanism: Consistent practice and coaching.
Benefits: Sustained function and adherence.

Mind-body and supportive education (the “MB-Gene-Ed” set)

16) Mindfulness-based stress reduction.
Description: Brief daily breathing/body-scan practice to calm stress.
Purpose: Reduce pain perception and anxiety.
Mechanism: Lowers sympathetic arousal; improves coping.
Benefits: Better sleep, mood, and pain tolerance.

17) Cognitive-behavioral strategies for chronic symptoms.
Purpose: Reframe unhelpful thoughts, boost activity and adherence.
Mechanism: Behavioral activation and cognitive restructuring.
Benefits: Lower distress, better participation in rehab.

18) Sleep hygiene coaching.
Purpose: Consolidate sleep to fight fatigue and pain.
Mechanism: Regular schedule, light control, caffeine limits.
Benefits: Daytime energy and mood improve.

19) Heat-management plan.
Purpose: Avoid heat-related worsening.
Mechanism: Cooling vests, hydration, air-conditioning.
Benefits: More stable walking and stamina.

20) Infection-prevention education.
Purpose: Prevent UTIs and chest infections that worsen function.
Mechanism: Hand hygiene, bladder routine, prompt treatment.
Benefits: Fewer setbacks and hospital visits.

21) Adrenal crisis action plan (education).
Purpose: Teach steroid sick-day rules and emergency hydrocortisone use.
Mechanism: Rapid cortisol replacement during illness/injury.
Benefits: Prevents life-threatening crises. NCBI

22) Family genetic counseling (“gene-education”).
Purpose: Explain X-linked inheritance; test relatives; plan pregnancies.
Mechanism: ABCD1 testing and carrier assessment.
Benefits: Early detection and timely care. NCBI

23) Community support and patient groups.
Purpose: Social, practical, and research updates.
Mechanism: Peer learning and resource sharing.
Benefits: Coping, advocacy, trial access. ALD Connect

24) Nutrition basics for adrenal and neuro health.
Purpose: Maintain stable energy, bowel regularity, bone health.
Mechanism: Adequate salt/fluids if adrenal-insufficient (per clinician advice), fiber, protein, vitamin D/calcium.
Benefits: Fewer dizzy spells, better bowel/bone health. NCBI

25) Safe mobility aids (cane, walker, wheelchair as needed).
Purpose: Keep independence and prevent falls.
Mechanism: External support compensates for weakness/spasticity.
Benefits: Safer community life and reduced injuries.

---

Drug treatments

(each: brief description with class, common adult dose range†, timing, purpose, mechanism, key side effects; always individualize with your clinician)

1) Hydrocortisone (glucocorticoid) for adrenal failure.
Class: Corticosteroid. Dose: Often 10–25 mg/day split (e.g., 10 mg AM, 5 mg midday, 5 mg PM); stress-dose per sick-day plan. Time: Daily, lifelong if adrenal-insufficient. Purpose: Replace missing cortisol. Mechanism: Restores stress hormone; stabilizes BP, energy, sodium/potassium balance. Side effects: Weight gain, glucose elevation, mood change, osteoporosis (use lowest effective dose). NCBI

2) Fludrocortisone for low aldosterone.
Class: Mineralocorticoid. Dose: Common 0.05–0.2 mg once daily, adjust by BP and renin. Purpose: Maintain salt and BP. Mechanism: Renal sodium retention, volume support. Side effects: High BP, low potassium, swelling—monitor. NCBI

3) Baclofen for spasticity.
Class: GABA-B agonist antispastic. Dose: 5 mg TID and titrate; max varies; intrathecal pump for severe cases. Purpose: Reduce tone and spasms. Mechanism: Inhibits spinal reflexes. Side effects: Drowsiness, weakness; taper to avoid withdrawal.

4) Tizanidine for spasticity.
Class: Alpha-2 agonist. Dose: 2–4 mg at night, titrate. Purpose: Alternative or add-on to baclofen. Mechanism: Decreases polysynaptic reflex activity. Side effects: Sedation, dry mouth, low BP; check liver enzymes.

5) Botulinum toxin injections for focal spasticity.
Class: Neuromuscular blocker (local). Dose: By muscle pattern every 3–4 months. Purpose: Relax problem muscles (adductors, calves). Mechanism: Blocks acetylcholine release. Side effects: Local weakness, pain at site.

6) Gabapentin for neuropathic pain.
Class: α2δ calcium-channel modulator. Dose: Often 300 mg nightly then titrate to 900–2400 mg/day in divided doses. Purpose: Burning/tingling pain control. Mechanism: Reduces central sensitization. Side effects: Sleepiness, dizziness.

7) Pregabalin (alternative).
Class: α2δ modulator. Dose: 75–150 mg/day in divided doses and titrate. Purpose/Mechanism: As above. Side effects: Edema, weight gain, sedation.

8) Duloxetine (if pain + mood).
Class: SNRI antidepressant/analgesic. Dose: 30–60 mg daily. Purpose: Neuropathic pain and depression/anxiety. Mechanism: Boosts serotonin/norepinephrine pain pathways. Side effects: Nausea, dry mouth, BP changes.

9) Intrathecal baclofen pump (device + drug).
Class: Spinal delivery of baclofen. Dose: Programmed by specialist. Purpose: Severe spasticity unresponsive to pills. Mechanism: High spinal concentration with fewer systemic effects. Side effects: Catheter/pump issues; withdrawal risk if interrupted.

10) Oxybutynin or Mirabegron for bladder urgency.
Class: Antimuscarinic or β3-agonist. Dose: Oxybutynin 2.5–5 mg TID (or ER once daily); Mirabegron 25–50 mg daily. Purpose: Reduce urgency/leakage. Mechanism: Detrusor relaxation. Side effects: Dry mouth/constipation (oxybutynin); BP rise (mirabegron).

11) Alpha-blockers (e.g., Tamsulosin) for retention.
Class: α1-blocker. Dose: 0.4 mg nightly. Purpose: Ease bladder outlet resistance. Mechanism: Relaxes prostate/urethra. Side effects: Dizziness, low BP.

12) PDE-5 inhibitors (e.g., Sildenafil) for erectile dysfunction.
Class: Phosphodiesterase-5 inhibitor. Dose: 25–100 mg as needed. Purpose: Improve erections. Mechanism: Enhances nitric oxide effect. Side effects: Headache, flushing; avoid with nitrates.

13) Bowel medicines (e.g., Polyethylene glycol; Loperamide when needed).
Class: Osmotic laxative; antidiarrheal. Dose: PEG 17 g daily; Loperamide as directed. Purpose: Manage constipation/diarrhea episodes. Mechanism: Stool water balance. Side effects: Bloating; constipation if overused.

14) Vitamin D + Calcium (if low or on steroids).
Class: Supplements. Dose: Vitamin D3 commonly 800–2000 IU/day; Calcium ~1000 mg/day from diet + supplements as advised. Purpose: Bone protection. Mechanism: Mineral and hormone support. Side effects: Hypercalcemia if excessive.

15) Investigational disease-modifying agents (clinical trials only).
Examples include VK0214 (TR-β agonist) and leriglitazone (PPAR-γ agonist). Early studies show VLCFA reduction and signals of activity, but no approved AMN-specific drug yet; enrollment is through trials. Side effects: study-specific. Viking Therapeutics InvestorRoomViking TherapeuticsClinicalTrialsInsightsminoryx.com+1

†Doses are typical starting points; your clinician individualizes based on age, kidney/liver function, drug interactions, and response.

---

Dietary molecular supplements

1. Vitamin D3—for bone/muscle health; dose often 800–2000 IU/day, adjusted by blood levels; supports calcium absorption and reduces fracture risk in low mobility or steroid use.

2. Calcium—diet first; supplement to reach ~1000 mg/day total; supports bone mineralization.

3. Omega-3 fatty acids—may help general cardiometabolic health and some neuropathic pain patients; mechanism: anti-inflammatory lipid mediators; dosing commonly 1–2 g/day EPA+DHA (check interactions).

4. Magnesium—may ease cramps; mechanism: calcium channel modulation; dose often 200–400 mg elemental/day; watch diarrhea and kidney function.

5. Vitamin B12—correct if low to support nerve function; dose varies (oral 1 mg/day or IM per protocol).

6. Folate—correct deficiency to support nerve repair pathways; typical 0.4–1 mg/day as advised.

7. Coenzyme Q10—general mitochondrial support (mixed evidence); 100–200 mg/day; may help fatigue in some.

8. Alpha-lipoic acid—used in diabetic neuropathy; antioxidant; dose often 300–600 mg/day (evidence in AMN is limited).

9. Fiber (psyllium/foods)—improves bowel regularity; titrate to effect with fluids.

10. Electrolyte salts (only if adrenal-insufficient and advised by clinician)—helps maintain volume and BP during heat or illness; dosing individualized.
    (Note: Lorenzo’s oil lowers VLCFA but does not treat established neurological disease; it may be considered in selected asymptomatic cases under specialist guidance. It is not a cure.) PubMedAlex TLCADC

---

Immunity booster / regenerative / stem-cell” options

1. Allogeneic hematopoietic stem-cell transplant (HSCT).
   Function/mechanism: Replaces immune cells that can clear brain inflammation in cerebral ALD. Use: Effective only for early cerebral ALD with enhancing brain lesions; not proven to help AMN myelopathy. Risks: Transplant risks. NCBI

2. Elivaldogene autotemcel (SKYSONA™) gene therapy.
   Function/mechanism: Autologous CD34+ cells are gene-modified to express ABCD1; slows neurologic decline in early, active cerebral ALD boys without a matched donor. Use: Cerebral ALD, ages 4–17; not an AMN treatment. U.S. Food and Drug AdministrationBoston Children’s Hospital

3. Intrathecal baclofen pump implantation (device-assisted therapy).
   Function: Delivers baclofen directly to spinal fluid to reduce spasticity when pills fail. Mechanism: Spinal GABA-B activation. Use: Severe spasticity in AMN to improve care and function.

4. Experimental small-molecule remyelination/metabolic agents (e.g., VK0214, leriglitazone).
   Function: Aim to normalize lipid metabolism/inflammation. Status: Clinical trials; not yet approved for AMN as of September 2025. Viking Therapeutics InvestorRoomInsights

5. Platelet-rich plasma / mesenchymal stem-cell infusions.
   Function claimed: “Regeneration.” Reality: No reliable evidence for AMN; avoid outside trials.

6. Immunomodulators for cerebral flare.
   Function: In cerebral ALD, some centers use bridging immunosuppression before HSCT; not standard for AMN. (Specialist care only.) NCBI

---

Surgeries/procedures

1. Intrathecal baclofen pump implantation—for severe spasticity to improve comfort, hygiene, and walking/positioning when oral drugs are not enough.

2. Selective tendon lengthening (e.g., Achilles)—to correct fixed contractures from long-standing spasticity; helps foot placement and brace fitting.

3. Orthopedic stabilization (hip/knee/foot)—for deformities causing pain or skin breakdown; improves seating and transfers.

4. Urologic procedures (e.g., botox to bladder, sphincterotomy, suprapubic catheter)—for refractory bladder dysfunction to protect kidneys and quality of life.

5. HSCT—only if cerebral ALD emerges and meets criteria; not for spinal AMN. NCBI

---

Preventions

1. Screen early and regularly for adrenal failure (ACTH stim, cortisol); treat promptly. NCBI

2. Stick to a spasticity and stretching routine to prevent contractures.

3. Keep up with falls-prevention and home safety (lighting, rails, footwear).

4. Prevent UTIs and constipation with bladder/bowel routines and fluids.

5. Follow sick-day steroid rules and carry emergency hydrocortisone if adrenal-insufficient. NCBI

6. Vaccinate per guidelines to reduce infection triggers.

7. Maintain bone health (vitamin D, weight-bearing, fall prevention).

8. Heat management (cooling, avoid overheating).

9. Regular monitoring with neurology/endocrinology (MRI when indicated to catch cerebral changes early). NCBI

10. Family genetic counseling and testing for early detection in relatives. NCBI

---

When to see doctors

• Right away / emergency: Severe weakness or sudden worsening walking; fever, vomiting, severe tiredness with known or suspected adrenal failure; fainting, very low BP, confusion; new severe headaches, vision loss, seizures, or behavior change (possible cerebral ALD). NCBI

• Soon (days–weeks): Increasing spasticity or falls; bladder/bowel change; new sexual dysfunction; weight loss, darkening skin, salt craving or dizziness; pain not controlled; sores from braces; repeated UTIs.

• Routine: Regular follow-up with neurology, endocrinology, rehab, and urology; periodic MRI if recommended; family planning and genetic counseling. NCBI

---

Foods to eat and to avoid

Eat more of:

1. Lean proteins (fish, poultry, legumes) for muscle repair.

2. High-fiber foods (whole grains, fruits, vegetables) for bowel health.

3. Hydrating fluids (water; oral rehydration if needed) to prevent constipation and dizziness.

4. Calcium-rich choices (dairy/fortified plant milks, leafy greens) for bones.

5. Vitamin D sources (fortified foods; clinician-guided supplements).

6. Magnesium-rich foods (nuts, seeds, beans) to ease cramps.

7. Potassium-rich fruits (bananas, oranges) unless told otherwise for adrenal/renal reasons.

8. Healthy fats (olive oil, nuts) for heart health.

9. B-vitamin sources (eggs, fish, fortified cereals) for nerve health.

10. Adequate salt only if adrenal-insufficient and advised by your clinician. NCBI

Limit/avoid:

1. Alcohol excess—worsens balance and sleep.

2. Very salty foods if you do not need fludrocortisone/salt; follow endocrine plan.

3. Sugary drinks—fatigue swings and weight gain.

4. Ultra-processed foods—low fiber, add inflammation.

5. Large heavy meals before activity—increase fatigue.

6. Dehydration—worsens spasms and constipation.

7. Excess caffeine late in the day—poor sleep.

8. Grapefruit if it interacts with your medicines (check labels).

9. High-heat environments during meals (spicy + hot room) if heat-sensitive.

10. Unverified “miracle” oils or stem-cell products marketed online—lack evidence and may be risky.

---

FAQs

1) Is AMN the same as ALD?
AMN is a common adult form (phenotype) of X-linked adrenoleukodystrophy. Same gene (ABCD1), different body areas involved. NCBI

2) Why does AMN mainly affect men?
The gene is on the X chromosome. Males have one X, so one faulty copy causes disease. Females have two X’s; many remain well, but some develop a milder myelopathy. NCBI

3) Can AMN be cured?
There is no cure yet for the spinal cord damage in AMN. Care focuses on adrenal replacement, rehab, symptom control, and trials when available. NCBI

4) Does gene therapy fix AMN?
No. Elivaldogene autotemcel (SKYSONA) is for early, active cerebral ALD in boys; it is not indicated for AMN. U.S. Food and Drug AdministrationBoston Children’s Hospital

5) Is bone-marrow transplant useful in AMN?
HSCT helps cerebral ALD if done early; it does not repair the spinal cord changes of AMN. NCBI

6) What about “Lorenzo’s oil”?
It lowers VLCFAs but does not stop neurologic decline once symptoms are present; sometimes discussed in asymptomatic boys only, under specialists. PubMedAlex TLC

7) How is adrenal failure checked?
Morning cortisol/ACTH and ACTH stimulation test; if low, hydrocortisone and sometimes fludrocortisone are started. NCBI

8) Will exercise make it worse?
No—proper physiotherapy helps walking, balance, and fatigue. Overexertion can backfire; pacing works best. PMC

9) Are there AMN-specific drugs in trials?
Yes. Agents like VK0214 and leriglitazone are being studied, but none is yet approved for AMN (as of Sept 2025). Ask about clinical trials. Viking Therapeutics InvestorRoomInsights

10) What scans are needed?
Brain MRI to watch for cerebral ALD; spinal MRI and nerve tests to track AMN. PMC

11) Can women be affected?
Yes—female carriers can develop a milder, later-onset myelopathy; they also need evaluation. NCBI

12) Why is bladder care important?
Untreated bladder problems raise UTI risk and kidney issues and worsen mobility; early urology input helps.

13) What raises risk of adrenal crisis?
Illness, injury, surgery, or vomiting in people with adrenal failure—use sick-day steroid rules and carry emergency hydrocortisone. NCBI

14) How often should I follow up?
Regularly with neurology, endocrinology, rehab, and urology; timing depends on your status. NCBI

15) Where can I find support?
National ALD groups and trial registries can help with education and research options. ALD Connect

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 09, 2025.